News

- Advance application acceptance starting today, service scheduled to launch on September 1 - TOKYO, August 24, 2020 - Astellas Pharma Inc. (Tokyo, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that it will start accepting advance applications and taking reservations for its exercise support service Fit-eNce®1, which encourages continous implementation of science-based...

Audentes Therapeutics, Inc., a wholly-owned subsidiary of Astellas, has issued a press release on August 20, 2020, to provide an update on the ASPIRO clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy (XLMTM), a serious, life-threatening neuromuscular disease characterized by extreme muscle weakness, respiratory failure, and early death. (PR Link :https://www.audentestx...

Astellas Pharma Inc. (“Astellas”) has launched an open innovation challenge “Astellas Rx+® Healthcare Innovation Challenge” (‘the Program’), with Agorize SAS (Head Office: Paris, France; Japan Country Manager: Ryota Nakazawa, “Agorize”)1, a company providing a global open innovation platform, aiming to create new Rx+® businesses2 beyond prescription drugs (Rx). Through the Program, Astellas calls...

Our heartfelt sympathy goes out to the people who have been affected by the Coronavirus Disease (COVID-19). With the continuing spread of COVID-19, we are, as part of our mission as a pharmaceutical company, taking various actions and measures to contribute to securing the safety of patients and alleviating strain on healthcare resources. The following are our activities and status to date in...